Study S002383

Evaluation Of Semaglutide Safety and Tolerability in Adults With Cocaine Use Disorder With and Without HIV

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT06691243
Acronym: STAC
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: QUADRUPLE
Status: ACTIVE_NOT_RECRUITING
Enrollment: 40
Start: 2025-08-07
Primary completion: 2027-01
Lead sponsor: University of Maryland, Baltimore
Conditions: Cocaine Use Disorder; HIV
Interventions: DRUG:Semaglutide; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:75N90024C00036

Registered primary outcomes

Safety of semaglutide in patients with cocaine use disorder (CUD) with and without HIV [16 weeks]
Tolerability of semaglutide in patients with cocaine use disorder (CUD) with and without HIV [16 weeks]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.